Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeNON PROFITAmerican College of Cardiology Supports FDA Efforts to End Access to...

American College of Cardiology Supports FDA Efforts to End Access to Menthol Cigarettes, Flavored Cigars

American College of Cardiology President Dipti Itchhaporia, MD, FACC, made the following statement on the U.S. Food and Drug Administration’s (FDA) commitment to ban menthol cigarettes and flavored cigarettes.

“Tobacco use is the leading cause of preventable death in the United States and a significant, modifiable risk factor for heart disease, which is the No. 1 cause of death in the United States. This should give us ample reason to take every action available to reduce tobacco’s impact on our society and public health. The American College of Cardiology is heartened to see the FDA’s recent commitment to advance bans on menthol flavored cigarettes and all flavored cigars. The ACC has joined with stakeholders in recent years to call for this change as an imperative to public health.

It is already known that flavored products are often targeted at and used by our youth population. It is why flavored e-cigarettes have already been banned and why we have raised the age to use tobacco products to 21.

We all understand the stakes of tobacco products and addiction on our communities’ health. Menthol cigarettes are well-known to increase youth initiation to smoking; they also increase addiction to nicotine and reduce success in smoking cessation.

We also know that menthol cigarettes have an incredibly high toll in the disease and death in the Black community, worsening existing and unacceptable health disparities. The ACC, the public health community, the FDA and Congress must work together on this vital issue with clear public health benefits of reducing tobacco-related death and disease.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy